RxDoctor Payments Data

Nanette Paredes, PA

Medical · Midland, TXNPI 1437175163

Payments from drug & device makers

$8,443in general payments, 2019–2025

Across 474 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$978
  • AbbVie$898
  • Teva Pharmaceuticals USA, Inc.$695
  • SK Life Science, Inc.$695
  • Novartis$635
  • Pfizer$574
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,20897%
  • Education$2353%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,443 in reported general payments places this provider in the 90th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$96,129
Medicare patients
386
Services billed
2,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine13$347,324
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5014$297,765
WakixPitolisant Hcl11$160,039
RytaryCarbidopa/Levodopa96$156,882
NourianzIstradefylline51$143,592
Kesimpta PenOfatumumab11$112,149
IngrezzaValbenazine Tosylate14$102,598
XcopriCenobamate67$84,784
CopaxoneGlatiramer Acetate13$74,599
NuplazidPimavanserin Tartrate15$72,699
BriviactBrivaracetam50$71,790
LamictalLamotrigine37$44,631
UbrelvyUbrogepant27$42,726
QuliptaAtogepant28$37,120
NuedextaDextromethorphan Hbr/Quinidine17$32,841

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga$574$347,32413 claims
Harmony Biosciences LLCWakix$143$160,03911 claims
Amneal Pharmaceuticals LLCRytary$196$156,88296 claims
Kyowa Kirin, Inc.Nourianz$190$143,59251 claims
Neurocrine Biosciences, Inc.Ingrezza$136$102,59814 claims
UCB, Inc.Briviact, Neupro$978$98,33671 claims
SK Life Science, Inc.Xcopri$695$84,78467 claims
AbbVieUbrelvy, Qulipta$898$79,84655 claims
Teva Pharmaceuticals USA, Inc.Copaxone$695$74,59913 claims
Acadia Pharmaceuticals IncNuplazid$35$72,69915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,490 medical providers in Texas.

Other medical in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →